Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/4262
Title: | 5-Fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring | Authors: | Yilmaz, A.U. Oztop, I. Ciloglu, A. Okan, T. Tekin, U. Yaren, Arzu. Somali, I. |
Keywords: | antihypertensive agent antineoplastic agent fluorouracil folinic acid heart enzyme oral antidiabetic agent adjuvant therapy adult aged ambulatory monitoring article cancer adjuvant therapy cancer combination chemotherapy cardiotoxicity clinical article clinical observation clinical trial continuous infusion diabetes mellitus digestive system cancer drug safety esophagus cancer female heart rate heart rhythm heart ventricle extrasystole Holter monitoring human hypertension liver cancer loading drug dose male medical record review metastasis multiple cycle treatment patient assessment priority journal side effect ST segment stomach cancer supraventricular premature beat symptom thorax pain Adult Aged Antimetabolites, Antineoplastic Cardiac Complexes, Premature Electrocardiography, Ambulatory Female Fluorouracil Gastrointestinal Neoplasms Humans Male Middle Aged Prospective Studies |
Abstract: | The cardiac toxicity of LV5FU2 (de Gramont) regimen which is a widely used chemotherapy regimen in gastrointestinal system cancers is not well defined. We aimed to evaluate the impact of this regimen on cardiac rhythm. Two Holter ECG recordings were obtained in all patients with gastrointestinal system cancers treated with LV5FU2 regimen as first-line chemotherapy (one before and the second during the first 24 h of chemotherapy). Records were reviewed for the heart rate, rhythm, atrial premature complexes (APC), ventricular premature complexes (VPC), grades according to Lown-Wolf grading system and ST segment changes. Holter ECG recordings were evaluated in 27 patients. In the baseline evaluation, neither clinical symptom nor ST segment changes were observed. During the treatment period, chest pain was observed in two patients without any cardiac enzyme and ST segment changes. Moreover, a decrease in mean heart rate, and an increase in the number and complexity of premature complexes secondary to treatment were observed. The mean heart rate, APC per hour and VPC per hour (±SD) before vs. during treatment were, respectively, 93.1 ± 16.4 vs. 81.6 ± 12.7 (p = 0.001), 18.9 ± 54.0 vs. 45.3 ± 53.8 vs. (p = 0.049) and 12.7 ± 29.6 vs. 38.1 ± 42.1 (p = 0.002). LV5FU2 regimen leads to a decrease in mean heart rate and a significant increase in APC and VPC which may lead to serious arrhythmias. These effects must be better understood for a safer administration of this useful and widely used drug regimen. © 2007 The Authors. | URI: | https://hdl.handle.net/11499/4262 https://doi.org/10.1111/j.1742-1241.2007.01323.x |
ISSN: | 1368-5031 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
37
checked on Dec 14, 2024
WEB OF SCIENCETM
Citations
34
checked on Dec 20, 2024
Page view(s)
60
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.